1. CIS 1055-009 09/26/16 Rueben Julfaian Merck & Co.
Rueben Julfaian CIS
CIS
09/26/16
Rueben Julfaian

2. Rueben Julfaian CIS
History Of Merck
Merck is one of the largest and oldest pharmaceutical companies that was started in 1668.
The family still owns around 70% of the parent company called the “Merck Group”.
The Company Merck & Co is actually a separate company founded by a relative who came to America. The company became nationalized in 1917.
The Merck Family owns the name in 193 countries while America and Canada belong to the corporation.
To the end

3. Products created by Merck & Co
Rueben Julfaian CIS
Products created by Merck & Co
Merck was the first to create vaccines for Hepatitis B, Chicken Pox, Mumps and Rubella.
A group of scientist discovered the thiazide family of diuretics which are used to treat blood pressure in the 1950s.
In 1987, Merck brought Mevacor into the market which was the first statin drug used to reduce cholesterol levels.
Primaxin was brought into market in This drug was the first member of the carbapenem class of antibiotics which is used to treat nasty drug resistant bacteria.

4. Acquisitions by the company
Rueben Julfaian CIS
Acquisitions by the company
H. K. Mulford Company
Charles E. Frosst Ltd
Schering-Plough
Diosynth
Organon International
OncoEthix
IOmet Pharma
Cubist Pharmaceutical
Sharp & Dohme, Inc
Medco which later on was sold to Express Scripts.
Nobilon
Intervet
Idenix Pharmaceuticals
Optimer Pharmaceuticals
Afferent Pharmaceuticals

5. Rueben Julfaian CIS
Controversy
Merck paid Elsevier a scientific medical journal to create articles that seemed to be independent and peer reviewed.
In 2008, Merck settled to pay more than 650 million dollars for failing to properly pay rebates to Medicaid.
Vioxx was created to replace older drugs like naproxen. It was found that this drug created an increase risk for heart attacks and was pulled off the market. Merck settled the court cases for around 4.85 billion dollars.

6. Major Competitors Amogen Allergan Reckitt Benckiser Novartis
Rueben Julfaian CIS
Major Competitors
Amogen
Reckitt Benckiser
GlaxoSmithKline
Boehringer Ingelheim
Daiichi Sankyo
Valeant Pharmaceuticals
Shire
Novo Nordisk
Allergan
Novartis
Pfizer
Sanofi
Janssen Pharmaceutical
Abbott Laboratories
AstraZeneca
Eli Lilly and Company

7. Stock Trend
Rueben Julfaian CIS

8. Corporate Infrastructure
Rueben Julfaian CIS
Corporate Infrastructure
Kenneth C. Frazier (CEO)
Sanat Chattopadhyay (VP)
Mirian M. Graddick-Weir (VPHR)
Julie L. Gerberding (CPO)
Michael J. Holston (VP General Counsel)
Robert M. Davis(CFO)

9. For More Information http://www.merck.com/index.html Back to the front
Rueben Julfaian CIS
For More Information
Back to the front